Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henriette Mersebach

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Diabetes Care|May 30, 2013
Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trialStephen C L Gough, Anuj Bhargava, Rajeev Jain, et al.
Hormone Research|January 31, 2004
Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adultsErika Hubina, Henriette Mersebach, Ase Krogh Rasmussen, et al.
Diabetes Care|May 10, 2014
Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trialGregory R Fulcher, Jens Sandahl Christiansen, Ganapathi Bantwal, et al.
American Journal of Obstetrics and Gynecology|October 2, 2007
Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjectsMoshe Hod, Peter Damm, Risto Kaaja, et al.
Diabetes Care|August 31, 2012
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trialIrl B Hirsch, Bruce Bode, Jean-Pierre Courreges, et al.
Diabetes Care|December 17, 2009
Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized studySimon Heller, Peter Damm, Henriette Mersebach, et al.
Diabetes Care|February 3, 2011
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialTim Heise, Cees J Tack, Robert Cuddihy, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 20, 2007
Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral densityHenriette Mersebach, Jan-Ove Johansson, Ase Krogh Rasmussen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Diabetes Care|May 30, 2013
Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trialStephen C L Gough, Anuj Bhargava, Rajeev Jain, et al.
Hormone Research|January 31, 2004
Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adultsErika Hubina, Henriette Mersebach, Ase Krogh Rasmussen, et al.
Diabetes Care|May 10, 2014
Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trialGregory R Fulcher, Jens Sandahl Christiansen, Ganapathi Bantwal, et al.
American Journal of Obstetrics and Gynecology|October 2, 2007
Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjectsMoshe Hod, Peter Damm, Risto Kaaja, et al.
Diabetes Care|August 31, 2012
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trialIrl B Hirsch, Bruce Bode, Jean-Pierre Courreges, et al.
Diabetes Care|December 17, 2009
Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized studySimon Heller, Peter Damm, Henriette Mersebach, et al.
Diabetes Care|February 3, 2011
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialTim Heise, Cees J Tack, Robert Cuddihy, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 20, 2007
Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral densityHenriette Mersebach, Jan-Ove Johansson, Ase Krogh Rasmussen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
Pageof 2